Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958776 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT00958776: Clinical Trial Phase 3 study, sponsored by BioCryst Pharmaceuticals.
NCT00958776 is a Phase 3 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 405 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00958776, a Phase 3 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.
Primary Outcome
Time to clinical resolution was defined as the time in hours from initiation of study treatment until normalization of at least 4 of the 5 signs within the respective normalization criteria, maintained for at least 24-hours. Time to clinical resolution was summarized by treatment group using the method of Kaplan-Meier. For subjects who did not experience clinical resolution, values were censored at the date of their last non-missing assessment of clinical resolution during the study (whether thi
Interventions
- DRUG Peramivir+SOC
- DRUG Placebo+SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Why NCT00958776 stopped before completion
NCT00958776 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Peramivir+SOC is the first listed.
NCT00958776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00958776 about?
NCT00958776 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza". A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.
What is the current status of trial NCT00958776?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2009-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00958776?
The interventions under investigation include: Peramivir+SOC (DRUG), Placebo+SOC (DRUG).
Who is sponsoring clinical trial NCT00958776?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00958776's enrollment target sits among peer trials
405 914th of 2000 higher than 1,087 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia